Replies to post #218070 on Biotech Values

[DewDiligence]

UMRX IPOs 6.64M* shares @$12.00 (low end of anticipated range):

https://globenewswire.com/news-release/2018/03/29/1455160/0/en/Unum-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Unum Therapeutics uses its proprietary antibody-coupled T cell receptor (ACTR) technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer.

The IPO went off at the low end of the anticipated range due to two belatedly disclosed deaths in the company’s clinical trial. The stock is down 4% as I’m typing.

Compare the above to the performance of FIXX, which IPOd yesterday (#msg-139639261).

*Assuming exercise of underwriter’s option.

[DewDiligence]

UMRX -23%/AH* on FDA clinical hold:

https://www.globenewswire.com/news-release/2019/07/02/1877594/0/en/Unum-Therapeutics-Announces-Regulatory-Update-from-Phase-1-Trial-with-ACTR087.html

*The stock is -30% today cumulatively, including the regular and AH sessions.